Drug Profile
Research programme: monoclonal antibody therapeutics - Kymab
Alternative Names: Anti-OPG Antibody; KY 1003; KY 1006; KY 1007; KY 1009; KY 1015; KY 1016; KY 1017; KY 1020; KY 1021; KY 1031; KY 1034; KY 1040; KY 1041; KY 1047; KY 1050; KY 1055; KY 1081; KY 7001; KY 7002; KY 7003; KY 7004; KY 7005; KY 7006; Ky3Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Kymab
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Immunostimulants; Inducible T-cell co-stimulator protein antagonists; Programmed cell death-1 ligand-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological disorders; Inflammatory bowel diseases; Pulmonary hypertension; Systemic lupus erythematosus
- Discontinued Cardiovascular disorders; Dyslipidaemias; Fibrosis; Graft-versus-host disease; Infections; Pain
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Pulmonary-hypertension in United Kingdom (Parenteral)
- 09 Apr 2021 Kymab has been acquired by Sanofi